Opthea Ltd has released a press release.
Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Opthea
- Opthea Meets Primary Safety Objective in DME Phase 1b trial
- Opthea reaches mid-way in recruitment for Ph2b wAMD trial
- Opthea Doses wAMD Patients in Europe and Israel
- Opthea Receives A$2.7m R&D Tax Incentive
- Opthea Initiates OPT-302 Diabetic Macular Edema Trial
Later from Opthea
- Opthea Appendix 4E and Annual Report 2018
- Opthea Receives Positive Safety Review for Ph2b wAMD Trial
- Opthea presents Ph1/2a wAMD data at Retina Society Meeting
- Opthea Doses First Patients in Australia for Phase 2a in DME
- Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea